These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1979261)

  • 21. Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children.
    Ghigo E; Mazza E; Corrias A; Imperiale E; Goffi S; Arvat E; Bellone J; De Sanctis C; Müller EE; Camanni F
    Metabolism; 1989 Jul; 38(7):631-3. PubMed ID: 2500577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women.
    Arvat E; Cappa M; Casanueva FF; Dieguez C; Ghigo E; Nicolosi M; Valcavi R; Zini M
    J Clin Endocrinol Metab; 1993 Feb; 76(2):374-7. PubMed ID: 8432781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of cholinergic tone in modulating the growth hormone response to growth hormone-releasing hormone in normal man.
    Giustina A; Bossoni S; Bodini C; Doga M; Girelli A; Buffoli MG; Schettino M; Wehrenberg WB
    Metabolism; 1991 May; 40(5):519-23. PubMed ID: 2023538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of dexamethasone on growth hormone (GH)-releasing hormone, arginine- and dopaminergic stimulated GH secretion, and total plasma insulin-like growth factor-I concentrations in normal male volunteers.
    Miell JP; Corder R; Pralong FP; Gaillard RC
    J Clin Endocrinol Metab; 1991 Mar; 72(3):675-81. PubMed ID: 1671785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone.
    Valcavi R; Zini M; Maestroni GJ; Conti A; Portioli I
    Clin Endocrinol (Oxf); 1993 Aug; 39(2):193-9. PubMed ID: 8370132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Corticosteroid-induced growth hormone secretion in normal and obese subjects.
    Muruais C; Cordido F; Morales MJ; Casanueva FF; Diéguez C
    Clin Endocrinol (Oxf); 1991 Dec; 35(6):485-90. PubMed ID: 1769129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging.
    Ghigo E; Goffi S; Arvat E; Nicolosi M; Procopio M; Bellone J; Imperiale E; Mazza E; Baracchi G; Camanni F
    Acta Endocrinol (Copenh); 1990 Aug; 123(2):169-73. PubMed ID: 2220258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different effects of pyridostigmine on growth hormone (GH) response to GH-releasing hormone in endogenous and exogenous hypercortisolemic patients.
    Borges MH; Castro RC; Kater CE; Lengyel AM
    Braz J Med Biol Res; 1993 Nov; 26(11):1191-200. PubMed ID: 7907904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects.
    Peñalva A; Muruais C; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1990 Feb; 70(2):324-7. PubMed ID: 2105328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing's syndrome.
    Leal-Cerro A; Pumar A; Villamil F; Astorga R; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 1993 Apr; 38(4):399-403. PubMed ID: 8319372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of cholinergic tone on growth hormone-releasing hormone-induced secretion of growth hormone in normal aging.
    Giusti M; Marini G; Sessarego P; Peluffo F; Valenti S; Caratti C; Giordano G
    Aging (Milano); 1992 Sep; 4(3):231-7. PubMed ID: 1420407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R; Valente F; Dieguez C; Zini M; Procopio M; Portioli I; Ghigo E
    J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction of salbutamol with pyridostigmine and arginine on both basal and GHRH-stimulated GH secretion in humans.
    Ghigo E; Arvat E; Gianotti L; Ramunni J; Maccario M; Camanni F
    Clin Endocrinol (Oxf); 1994 Jun; 40(6):799-802. PubMed ID: 8033372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth hormone (GH) autofeedback on GH response to GH-releasing hormone. Role of free fatty acids and somatostatin.
    Pontiroli AE; Lanzi R; Monti LD; Sandoli E; Pozza G
    J Clin Endocrinol Metab; 1991 Feb; 72(2):492-5. PubMed ID: 1671389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pyridostigmine fails to increase either spontaneous or GHRH-stimulated GH secretion during day or night in growth hormone-insufficient children.
    Kirk JM; Ross RJ; Trainer PJ; Froud AL; Davies SC; Savage MO; Besser GM
    Clin Endocrinol (Oxf); 1991 May; 34(5):407-11. PubMed ID: 2060150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
    Cordido F; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired growth hormone (GH) response to pyridostigmine in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion.
    Giustina A; Bossoni S; Cimino A; Pizzocolo G; Romanelli G; Wehrenberg WB
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1486-90. PubMed ID: 2229305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adrenergic and cholinergic involvement in basal and growth hormone-releasing hormone-stimulated growth hormone secretion in glucocorticoid-treated rats.
    Giustina A; Misitano V; Voltz D; Piering A; Wehrenberg WB
    Endocr Res; 1995 Nov; 21(4):719-32. PubMed ID: 8582323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repeated administration of growth hormone-releasing hormone with or without previous administration of pyridostigmine in insulin-dependent diabetes mellitus.
    Martina V; Bruno G; Tagliabue M; Maccario M; Bertaina S; Zumpano E; Arvat E; Ghigo E; Camanni F
    Horm Metab Res; 1997 Apr; 29(4):180-3. PubMed ID: 9178028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.